PO110 ASSESSMENT OF EARLY PROGRESSION RISK FOR PATIENT WITH ESR1 MUTATIONS AND HORMONE RECEPTOR POSITIVE (HR+)/HER2-NEGATIVE METASTATIC BREAST CANCER (MBC)

Trastuzumab, other innovative drugs became available, including lapatinib.Therefore, the Dushanbe City Counseling Center, together with the Republican Cancer Institute and the NGO Avesta, recruited the humanitarian drug lapatinib to treat women with metastatic cancer and HER-positive status.A total of 56 women with advanced and metastatic cancer were selected.The primary diagnosis of disseminated breast cancer was in 19 women (34%), and metastatic relapse was in 37 women(66%).CNS metastases were found in 11 women, and liver metastases were found in 26 women.Eleven women (19%) received anthracycline therapy before lapatinib administration.The women were separated by age: 31 women were in the 45-60-year group, and 25 women were in the 60-75 year group.All women received positive IHC and FISH tests to confirm HER-positive status.Results of lapatinib treatment and the drug's effect on metastatic cancer: Women were treated with lapatinib for 24 weeks at a dose of 1,250 mg orally once daily on Days 1-21 continuously in combination with capecitabine.After treatment evaluation, brain metastases had not progressed in 7(12%) women, and two women experienced a decrease in the size of their metastases.8(14%) women with liver metastases had no progression of liver metastases, and 23 women had progression and growth of metastases.Impact of humanitarian delivery of lapatinib on the cancer care system: 1.The Cancer Institute opened a lab to diagnose HER2 status. 2. The Oncology Institute started working on a protocol for the treatment of women with advanced and metastatic cancer, which is vital for a country with limited resources.